AYA cancer survivors struggle with social functioning

Doctor consults with
cancer patient and her father
Photo by Rhoda Baer
New research suggests young cancer survivors struggle to get their social lives “back to normal” within the first 2 years of their diagnosis. The study showed that adolescents and young adults (AYAs) with cancer had significantly worse social functioning than the general population around the time of cancer diagnosis as well as 1 year and 2 years later. These findings were published in Cancer. “The research is important to help these young survivors better reintegrate into society,” said study author Brad Zebrack, PhD, of the University of Michigan in Ann Arbor. [Read Article]

FDA grants orphan designation to gilteritinib in AML

AML cells
Image by Lance Liotta
The US Food and Drug Administration (FDA) has granted orphan drug designation to gilteritinib for the treatment of patients with acute myeloid leukemia (AML). Gilteritinib, an inhibitor of FLT3 and AXL, has demonstrated activity against FLT3 internal tandem duplication (ITD) as well as tyrosine kinase domain, 2 mutations that are seen in up to a third of patients with AML. Astellas Pharma Inc. is currently investigating gilteritinib in phase 3 trials of AML patients. Results from a phase 1/2 study of gilteritinib in AML were presented at the 2017 ASCO Annual Meeting. [Read Article]

FDA approves generic tranexamic acid

Vials of drug
Photo by Bill Branson
Zydus Cadila has received approval from the US Food and Drug Administration (FDA) to market a tranexamic acid product for use in patients with hemophilia. The company’s product—Tranexamic Acid Injection, 1000 mg/10 mL (100 mg/mL) Single Dose Vial—can be used to prevent or reduce bleeding in hemophilia patients undergoing tooth extraction. Zydus Cadila’s tranexamic acid will be produced at a manufacturing facility in Moraiya, Gujarat, India. [Read Article]